Main . Cervical cancer is the fourth leading cause of cancer death in women, resulting in 342,000 deaths worldwide in 2020 (ref.1). CSCC is the most common histological type of cervical cancer. Although localized disease has a favorable prognosis, the 5-year survival rate of late-stage, metastatic or recurrent CSCC is only 16.5% (ref.2). Immune-checkpoint blockade (ICB) has radically changed the paradigm in clinical oncology3, but in advanced cervical cancer, anti-PD-L1...